Carregant...
Sitravatinib potentiates immune checkpoint blockade in refractory cancer models
Immune checkpoint blockade has achieved significant therapeutic success for a subset of cancer patients; however, a large portion of cancer patients do not respond. Unresponsive tumors are characterized as being immunologically “cold,” indicating that these tumors lack tumor antigen-specific primed...
Guardat en:
| Publicat a: | JCI Insight |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Clinical Investigation
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6238734/ https://ncbi.nlm.nih.gov/pubmed/30385724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.124184 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|